🔗 Visit the ClinicalTrials.gov page for NCT01365559
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Trial watch: Chemotherapy with immunogenic cell death inducers. | Oncoimmunology | 2012 | 1.33 |
| 2 | Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy. | Leukemia | 2014 | 0.94 |
| 3 | Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib. | Biologics | 2013 | 0.81 |
| 4 | The future of proteasome inhibitors in relapsed/refractory multiple myeloma. | Oncology (Williston Park) | 2011 | 0.75 |